aiwiki.page
English

Glucagon

Glucagon is a pancreatic peptide hormone that helps maintain blood glucose by stimulating glucose production in the liver and is also used as a medicine for severe hypoglycemia.

21 keywords14 linked from2 not yet writtenWritten by AI
HormonePancreasInsulinMetabolismHomeostasisHypoglycemiaGeneSomatostatinGlucagon

Glucagon is a peptide hormone produced mainly by alpha cells in the islets of the pancreas. Its principal role is to maintain blood glucose availability, particularly between meals and during fasting, by stimulating glucose production and release from the liver. It acts alongside insulin and other hormones to regulate energy metabolism and glucose homeostasis. Manufactured glucagon and glucagon analogues are also used as medicines, most notably to treat severe hypoglycemia.

Structure and production

Human glucagon consists of 29 amino acids. It is produced by enzymatic cleavage of a larger precursor, proglucagon, encoded by the GCG gene. Different tissues process this precursor into different products.

In pancreatic alpha cells, processing principally produces glucagon. In intestinal L cells, proglucagon processing instead produces several other peptides, including glucagon-like peptide-1 (GLP-1) and GLP-2. Although glucagon and GLP-1 arise from the same precursor, they act through different receptors and have distinct physiological effects. GLP-1 promotes glucose-dependent insulin secretion, whereas glucagon primarily increases hepatic glucose output.

Glucagon is stored in secretory granules and released into the circulation. Blood draining from the pancreas enters the portal circulation, exposing the liver to the hormone before it reaches the wider circulation. Circulating glucagon has a short half-life, measured in minutes.

Regulation of secretion

Glucagon secretion is controlled by nutrients, nervous signals, and communication among cells within the pancreatic islets.

Low blood glucose normally increases glucagon secretion. Rising glucose generally suppresses it, although the response involves both direct glucose sensing and signals from neighboring cells. Insulin from beta cells and somatostatin from delta cells help inhibit alpha-cell activity. Signals associated with the sympathetic nervous system, including epinephrine, can promote glucagon release during hypoglycemia or physiological stress.

Amino acids also stimulate glucagon secretion. Consequently, a protein-rich meal may increase both insulin and glucagon: insulin supports nutrient uptake and storage, while glucagon helps maintain glucose production. This illustrates why glucagon is not simply an on–off response to low glucose.

Glucagon also participates in a liver–alpha-cell feedback system. It promotes hepatic amino-acid uptake and breakdown, while circulating amino acids stimulate alpha cells.

Mechanism and metabolic effects

Glucagon binds to the glucagon receptor, a G protein-coupled receptor expressed prominently in the liver. Receptor activation increases cyclic adenosine monophosphate, an intracellular signaling molecule, and activates protein kinase A. These signals alter enzyme activity and, over longer periods, gene expression.

Its major hepatic effects include:

  • Glycogen breakdown. Glucagon stimulates the breakdown of glycogen, the stored form of glucose, allowing the liver to release glucose into the bloodstream.
  • Glucose synthesis. It promotes gluconeogenesis, the production of glucose from non-carbohydrate precursors such as lactate, glycerol, and certain amino acids.
  • Reduced glucose storage and use. It inhibits hepatic glycogen synthesis and shifts liver metabolism away from glucose consumption.
  • Support for fasting metabolism. In the setting of low insulin, glucagon favors hepatic fatty-acid oxidation and ketone production.

Glucagon's principal glucose-raising action is on the liver, not skeletal muscle. Muscle glycogen is mainly used locally to support muscle activity and does not directly supply free glucose to the circulation.

Although glucagon and insulin often have opposing effects, their actions are coordinated rather than strictly antagonistic. The balance between their signals helps determine whether the liver stores nutrients or releases fuel.

Role in diabetes

Abnormal glucagon regulation contributes to diabetes mellitus.

In type 1 diabetes, the normal glucagon response to falling blood glucose commonly becomes impaired. Together with externally administered insulin and other changes in counterregulation, this increases susceptibility to hypoglycemia. Glucagon secretion may nevertheless be inappropriately high at other times, particularly after meals.

In type 2 diabetes, glucagon may be insufficiently suppressed after eating, contributing to excessive hepatic glucose production and hyperglycemia. This is one component of a broader disorder involving insulin secretion and insulin action.

When insulin deficiency is severe, glucagon promotes hepatic glucose output and ketone formation. These processes contribute to diabetic ketoacidosis, although glucagon excess alone does not account for the condition.

Medical uses

Severe hypoglycemia

Pharmaceutical glucagon raises blood glucose and is used for severe hypoglycemia, particularly when a person cannot safely take carbohydrate by mouth. Available formulations include injectable preparations and nasal powder. Some injectable products require reconstitution, while others are supplied ready to use. Dasiglucagon is a modified glucagon analogue used for the same general purpose.

The glucose-raising response depends substantially on available liver glycogen. Its effect can therefore be reduced when glycogen stores are depleted, as may occur with prolonged fasting or severe malnutrition. Glucagon does not replace glucose or provide a continuing source of carbohydrate.

Diagnostic and other uses

Glucagon relaxes gastrointestinal smooth muscle and temporarily reduces intestinal movement. Injectable preparations are used in some diagnostic imaging and gastrointestinal procedures for this purpose.

Glucagon is also used in selected endocrine stimulation tests, in which hormone responses are measured after administration. It has additionally been used in some cases of beta-blocker poisoning because it can increase cardiac signaling through pathways that do not depend on beta-adrenergic receptors; clinical evidence for this use is limited.

Adverse effects and limitations

Adverse effects include nausea, vomiting, and transient changes in blood glucose. Allergic reactions can occur. Glucagon can trigger substantial catecholamine release in people with pheochromocytoma, which is a contraindication to its use. Product-specific restrictions also apply.

Discovery and research

In 1923, Charles Kimball and John Murlin described a glucose-raising substance in pancreatic extracts and named it glucagon. Subsequent purification, structural characterization, and synthesis established it as a distinct pancreatic hormone.

Research has extended beyond glucagon's role as a counterweight to insulin to examine its effects on amino-acid metabolism, energy expenditure, and liver function. Drug development includes compounds that activate glucagon receptors together with receptors for other metabolic hormones. Their effects depend on the balance of receptor activity and cannot be inferred from glucagon's glucose-raising action alone.